The presentation will begin In:
Days
Hours
Minutes
Abstract
Dr. Sabine Hazan
2025 Presentation(s):
The presentation will begin In:
Days
Hours
Minutes
Abstract
*General Session also counted towards CME Credits//
Background. The incidence of autism spectrum disorder (ASD) in the United States is approximately 1 in 36 children according to 2024 data. The gut microbiome is emerging as a potential therapeutic option to manage and alleviate symptoms of ASD. We have previously reported on a nineteen-year-old adolescent with severe ASD, treated with familial fecal microbiota transplantation (FMT) who showed improvements not only gut on the microbiome composition but also in ASD clinical symptoms. In this study we seek to compare the gut microbiome of ASD patients with their healthy sibling and with non-familial healthy controls, to determine whether Bifidobacterium is associated with ASD.
Methods. Fecal samples from 21 ASD patients (ages 0-10 years old), 23 healthy siblings and 6 non-familial healthy controls were collected at ProgenaBiome laboratories. Microbiota composition was compared using DNA quantification, purification, and normalization using shotgun methodology and next-generation sequencing (NGS) on the Illumina NextSeq with 500/550 High-Output Kits V.2.5 for 300 cycles. Data were processed through the OneCodex bioinformatics system to determine microbiota composition and relative abundances of top genera and phyla. A two-sample t-test was used to evaluate statistical significance.
Results. The gut microbiome of ASD patients had lower abundance of Bifidobacterium (p<0.006), compared to that of their neurotypical siblings. Similarly, when compared to non-familial individuals, ASD patients had statistically significant lower abundance of Bifidobacterium (p<0.001).
Conclusions. These data suggest that gut Bifidobacterium is somehow associated with ASD. Larger studies are needed to confirm these findings.
Speaker Bio:
Born in Morocco, Dr. Sabine Hazan has always been dedicated to understanding life. She sought a career in medicine and was accepted to medical school based on outstanding research on obesity conducted as an undergraduate. She completed her residency at the University of Miami during the peak of the HIV epidemic, treating extremely ill patients at Jackson Memorial Hospital and in the local jail. There, she was awarded two prizes for her research. After completing her residency, Dr. Hazan became the first woman gastroenterology fellow at the University of Florida. There, she completed a year of research and presented her findings in poster format at the American College of Gastroenterology (ACG) National Meeting. It was at that moment that she was approached by the esteemed Dr. Neil Stollman. He told her that the future of medicine lies in the microbiome. For her exceptional work with visceral hyperalgesia she was awarded the Dean’s Research Award. Dr. Stollman is now an expert and leader on fecal transplant and Clostridioidesdifficile (C.diff) and serves on the governing board of the ACG.
share this speaker:
Facebook
Twitter
LinkedIn
Email